Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00099255 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-30 / ADCETRIS®)

Study Title
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma (NCT00099255)

Trial Description
This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of the antibody-drug conjugate SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.

This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Condition: Large Cell Lymphoma
  • Interventions:
    • Drugs used in this trial
      • SGN-30
  • Phase: II
  • Estimated Enrollment: 40
  • Start: September 2004
  • Completion: February 2007
  • Last verified: December 2014

Study Schematic

NCT00099255 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar